High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Read more about High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Read more about Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. Read more about Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. Read more about Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
Long-term survivors of gastric cancer: a California population-based study. Read more about Long-term survivors of gastric cancer: a California population-based study.
Progress against solid tumors in danger: the metastatic breast cancer example. Read more about Progress against solid tumors in danger: the metastatic breast cancer example.
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. Read more about Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. Read more about Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.
Reversing hormone resistance: have we found the golden key? Read more about Reversing hormone resistance: have we found the golden key?
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Read more about Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
